PRELIMINARY NOTICE OF MEETING

The shareholders of the company are hereby invited to attend the Combined Ordinary and Extraordinary General Meeting of Shareholders to be held at 8:30 a.m. on June 15, 2017, at the registered office:
177-181 avenue Pierre Brossolette – 92120 Montrouge, France, to deliberate on the following agenda:

**Agenda**

**Ordinary resolutions:**

1. Approval of the financial statements for the year ended December 31, 2016;
2. Approval of the consolidated financial statements for the year ended December 31, 2016;
3. Allocation of income for the year;
4. Special report by the Statutory Auditors on related-party agreements and commitments and approval of these agreements;
5. Renewal of Deloitte & Associés as Statutory Auditor;
6. Non-renewal and non-replaced of the BEAS firm as alternate auditor;
7. Appointment of Ms. Julie O’Neill as Director, in addition to the current Board members;
8. Amount of the directors’ fees allocated to Board members;
9. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and the benefits of any kind to be attributed to Pierre-Henri Benhamou, Chairman and Chief Executive Officer;
10. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and the benefits of any kind to be attributed to David Schilansky, Executive Vice President (Chief Operating Officer);
11. Approval of the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary compensation components and the benefits of any kind to be attributed to Laurent Martin, Executive Vice President;
12. Authority to be given to the Board of Directors to buy back its own shares pursuant to Article L. 225-209 of the Commercial Code, the duration of the authorization, purpose, conditions, ceiling, and suspension in a public offering period;
Extraordinary resolutions:

13. Authorization to be granted to the Board of Directors to cancel the shares bought back by the company in the context of the mechanism stipulated by Article L. 225-209 of the Commercial Code, length of the authorization, cap, and suspension in a public offering period.

14. Authorization given to the Board of Directors to grant stock subscription and/or purchase options to members of salaried employees and/or certain corporate officers of the company or affiliated companies, shareholder waiver of their preemptive rights, duration of the authorization, maximum amount, exercise price, maximum term of the option;

15. Authorization to the Board of Directors to allocate free existing and/or future shares to salaried employees and/or certain corporate officers of the company or affiliated companies, shareholder waiver of their preemptive rights, duration of the authorization, maximum amount, duration of vesting periods specifically in case of disability and holding periods, if any;

16. Delegation of powers to be granted to the Board of Directors to issue stock warrants (BSA), warrants for the subscription and/or purchase of new and/or existing shares (BSAANE), and/or warrants for subscription and/or acquisition of new and/or existing redeemable shares (BSAAAR) eliminating preemptive rights, reserved for a category of persons, maximum par value of the capital increase, duration of the delegation, exercise price, suspension during a public offering period;

17. Delegation of powers to be granted to the Board of Directors to increase capital through the issue of shares of commons stock and/or securities giving rights to equity, without preemptive subscription right, in favor of the members of a company savings plan, pursuant to Articles L. 3332-18 et seq. of the Labor Code, duration of the delegation, maximum nominal amount of the capital increase, issue price, possibility of allotting free shares pursuant to Article L. 3332-21 of the Labor Code, suspension during a public offering period;

18. Amendment to Article 36 of the bylaws;

19. Powers to complete formalities.

Proposed Resolutions

Ordinary resolutions:

First Resolution - Approval of the individual financial statements for the year ended December 31, 2016

The Shareholders’ Meeting, after a review of the reports of the Board of Directors, the Chairman of the Board and the Statutory Auditors on the year ended December 31, 2016, hereby approves, as they have been presented, the annual financial statements established on said date, which show a loss of €81,109,367.88.
Second Resolution - Approval of the consolidated financial statements for the year ended December 31, 2016

The Shareholders’ Meeting, after a review of the reports of the Board of Directors, the Chairman of the Board and the Statutory Auditors on the consolidated financial statements for the year ended December 31, 2016, hereby approves these statements, as they have been presented, which show a loss of €114,530,959.91.

Third Resolution - Allocation of income for the year

On the recommendation of the Board of Directors, the Shareholders’ Meeting hereby decides to allocate the full loss for the year ended December 31, 2016, to retained earnings loss, which would thus increase from (€83,335,806) to (€164,445,174).

Pursuant to Article 243 bis of the General Tax Code, the Meeting notes that it was reminded that no dividend nor revenue has been distributed in the past three financial years.

Fourth Resolution - Special report from the Auditors on related-party agreements and commitments and approval of these agreements

Voting on the special report of the Statutory Auditors on related-party agreements and commitments presented to it, the Shareholders’ Meeting approves the new agreements described therein.

Fifth Resolution - Renewal of Deloitte & Associés as statutory auditor

On the recommendation of the Board of Directors, the Shareholders’ Meeting reappoints Deloitte & associés, whose term of office expires at the end of this Meeting, as statutory auditor for a term of six years, until the end of the Annual Shareholders’ Meeting to be held in 2023 called to approve the financial statements for the year ended December 31, 2022.

Deloitte has declared that it accepts this appointment.

Sixth Resolution - Non-renewal and non-replacement of BEAS as alternate auditor

The Shareholders’ Meeting, after noting that the term of office of BEAS as alternate auditor expires at the end of this Meeting, decides on the recommendation of the Board of Directors not to renew or replace it.

Seventh Resolution - Appointment of Ms. Julie O’Neill as Director, in addition to the current members of the Board

The Shareholders’ Meeting elects Ms. Julie O’Neill, 21 Garville Road, Rathgar, Dublin (Ireland) to the Board of Directors, in addition to the current members of the Board, for a term of two years, to expire at the end of the Meeting held in 2019 and called to approve the financial statements for the previous year.
Eighth Resolution - Amount of directors’ fees allocated to Board members

The Shareholders’ Meeting raises the total annual amount of the directors’ fees to be allocated to the Board of Directors from €350,000 to €600,000. This decision, which is applicable to the current year, will be maintained until a new decision.

Ninth Resolution - Approval of the principles and criteria for determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits attributable to Pierre-Henri Benhamou, Chairman and Chief Executive Officer

The Shareholders’ Meeting, voting pursuant to Article L. 225-37-2 of the Commercial Code, hereby approves the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits of any kind attributable, because of his position, to Pierre-Henri Benhamou, Chairman and Chief Executive Officer, as presented in the report attached to the report described in Articles L. 225-100 and L. 225-102 of the Commercial Code.

Tenth Resolution - Approval of the principles and criteria for determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits attributable to David Schilansky, Executive Vice President (Chief Operating Officer)

The Shareholders’ Meeting, voting pursuant to Article L. 225-37-2 of the French Commercial Code, hereby approves the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits of any kind attributable, because of his position, to David Schilansky, Executive Vice President, as presented in the report attached to the report described in Articles L. 225-100 and L. 225-102 of the Commercial Code.

Eleventh Resolution - Approval of the principles and criteria for determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits attributable to Laurent Martin, Executive Vice President

The Shareholders’ Meeting, voting pursuant to Article L. 225-37-2 of the French Commercial Code, hereby approves the principles and criteria for the determination, distribution and allocation of the fixed, variable and extraordinary components of his total compensation and the benefits of any kind attributable, because of his position, to Laurent Martin, Executive Vice President, as presented in the report attached to the report described in Articles L. 225-100 and L. 225-102 of the Commercial Code.

Twelfth Resolution - Authorization to be given to the Board of Directors for the company to buy back its own shares pursuant to Article L. 225-209 of the French Commercial Code

The Shareholders’ Meeting, having reviewed the report of the Board of Directors, empowers the Board of Directors, for a period of eighteen months, pursuant to Articles L. 225-209 et.seq. of the Commercial Code, to buy back, on one or more occasions and at the times of its choosing, company shares up to a limit of 10% of the number of shares comprising the share capital,
adjusted, if necessary, to take into account the potential increase or reduction in capital that may take place during the program.

This authorization cancels the authorization granted to the Board of Directors by the Shareholders’ Meeting of June 21, 2016, in its Fifth Ordinary Resolution.

The shares may be bought back in order to:

- support the secondary market or liquidity for DBV TECHNOLOGIES shares through an investment service provider under a liquidity contract that complies with the AMAFI's Code of Ethics as permitted by legislation; it is specified that in this context, the number of shares counted in order to calculate the aforementioned limit is the number of shares purchased, less the number of shares resold.

- hold the purchased shares and ultimately return them for future exchange or as payment for external growth transactions.

- provide coverage to meet obligations arising from stock option plans and/or free share allocation plans (or similar plans) for the group’s employees and/or corporate officers, as well as all share allocations arising under company or group employee savings plans (or similar plans), employee profit-sharing plans and/or any other form of share allocation arrangement for the group’s employees and/or corporate officers.

- hedge the securities giving access to the company’s shares, pursuant to current regulations.

- where applicable, cancel the shares acquired, subject to the authorization to be granted by this Shareholders’ Meeting in the thirteenth Resolution submitted to the Extraordinary Meeting.

These share purchases may be executed by any means, including the acquisition of blocks of shares, at the times deemed appropriate by the Board of Directors; it is specified that the Board may not, without the prior authorization of the Shareholders’ Meeting, use this authority during a public offer period initiated by a third party for the shares of the company until the end of the offer period.

The company does not intend to use options or derivatives.

The maximum purchase price is set at €200 per share. In the event of a capital transaction, in particular a stock split or reverse split, or the allotment of bonus shares to shareholders, the above-mentioned amount shall be adjusted in the same proportions (multiplier coefficient equal to the ratio between the number of shares comprising the capital before the transaction and the number of shares after the transaction).

The maximum transaction amount is therefore set at €150,000,000.

The Shareholders’ Meeting hereby authorizes the Board of Directors to carry out these transactions, set the terms and conditions and methods thereof, finalize all agreements and complete all formalities.
Extraordinary resolutions:

Thirteenth Resolution - Authorization to be granted to the Board of Directors to cancel the shares bought back by the company pursuant to Article L. 225-209 of the Commercial Code

The Shareholders’ Meeting, after a reading of the Board of Directors’ report and the Statutory Auditors’ report:

1) Grants the Board of Directors the authority to cancel, at its sole discretion, on one or more occasions, up to a limit of 10% of the capital calculated on the date of the cancellation decision, minus any shares cancelled in the previous 24 months, the shares which the company holds or may hold as the result of the purchases made pursuant to Article L. 225-209 of the Commercial Code, and to reduce the capital stock accordingly pursuant to the laws and regulations in force;

2) Sets the validity of this authorization at twenty-four months from the date of this authorization;

3) Decides that the Board of Directors may not, without prior authorization from the Shareholders’ Meeting, use this authorization as of the date of filing by a third party of a public offer for the shares of the company until the end of the offer period;

4) Grants all powers to the Board of Directors to execute the necessary transactions for such cancellations and the related reductions of the capital, stock, amend the company’s bylaws accordingly and perform all formalities required.

Fourteenth Resolution - Authorization to be given to the Board of Directors to award stock options for new and/or existing shares to salaried employees (and/or certain corporate officers)

The Shareholders’ Meeting, after a reading of the report of the Board of Directors and the Statutory Auditors’ special report:

1) Hereby authorizes the Board of Directors, pursuant to the provisions of Articles L. 225-177 to L. 225-185 of the Commercial Code, to grant, on one or more occasions, for the benefit of the beneficiaries named below, options giving the right to subscribe new shares of the company to be issued in a capital increase or to purchase existing shares of the company coming from buybacks made as required by law;

2) Sets the term of validity of this authorization at thirty-eight months from the date of this Shareholders’ Meeting;

3) Decides that the beneficiaries of these options may only be:
   - some or all members of staff, or certain categories of staff, of DBV TECHNOLOGIES, and where appropriate, those companies or economic interest groups related to it under the conditions of Article L. 225-180 of the Commercial Code;
   - secondly, those corporate officers who meet the conditions set out in Article L. 225-185 of the Commercial Code.
4) The total number of options that may be granted by the Board of Directors under this authorization will not grant the right to subscribe to or purchase a number of shares greater than 5.5% of the capital stock existing on the date of this Meeting;

5) Decides that the share subscription and/or purchase price by the beneficiaries will be set on the date the options are granted by the Board of Directors in accordance with the regulations in effect and may not be less than the average price over the twenty trading days preceding the date of the award decision;

6) Decides that the exercise of the stock options for new or existing shares by the corporate officers of the company shall be subject to the achievement of performance conditions to be set by the Board of Directors;

7) Decides that no options may be granted:
   - within the ten trading days before and after the date on which the consolidated financial statements are made public,
   - or in the period between the date on which the company’s corporate bodies are made aware of information that, if made public, could have a significant impact on the trading price of the company’s securities, and the date ten trading days after said information is made public,
   - less than twenty trading days after the detachment of shares from a coupon giving access to a dividend or capital increase.

8) Notes that this authorization includes, to the beneficiaries of the options giving access to shares, an express waiver by shareholders of their pre-emptive rights to subscribe shares to be issued as and when the options are exercised;

9) Delegates all powers to the Board of Directors to set the other terms and conditions for the granting of options and their exercise, in particular to:
   - set the conditions under which the options shall be awarded and define the list or the categories of beneficiaries as stipulated above; determine, where appropriate, the seniority and performance conditions that must be met by these beneficiaries; determine the conditions under which the price and number of shares must be adjusted, particularly in the cases set out under Articles R. 225-137 to R. 225-142 of the Commercial Code;
   - define the exercise period(s) for the options granted, with the understanding that the term of the options may not exceed a period of ten (10) years from the grant date;
   - provide the option to temporarily suspend the exercise of options for a maximum period of three months in the event that financial transactions are performed involving the exercise of a right attached to shares;
   - as applicable, make the acquisitions of the necessary shares within the framework of the share buyback program and allocate them to the option plan,
   - proceed with all acts and formalities required to make final those capital increases that may, if necessary, be performed pursuant to the authorization granted by this resolution; amend the articles of association accordingly and generally to do whatever is necessary;
   - at its own discretion and if it sees fit, impute the cost of increases in share capital to the amount of the associated premiums and deduct the necessary sums from this amount to bring the statutory reserve to one tenth of the new share capital after each increase.

10) Notes that this authorization cancels the unused portion, of any prior authorization having the same purpose.
Fifteenth Resolution - Authorization to be given to the Board of Directors to allot free shares to salaried employees and/or certain corporate officers

The Shareholders’ Meeting, after a reading of the Board of Directors’ report and the Statutory Auditors’ special report, hereby authorizes the Board of Directors, on one or more occasions, in accordance with Articles L. 225-197-1 and L. 225-197-2 of the Commercial Code, to allot existing or future shares, of common stock to:

- Salaried employees of the company or companies that are directly or indirectly affiliated with it as defined by Article L. 225-197-2 of the Commercial Code,
- and/or corporate officers who meet the conditions set out in Article L. 225-197-1 of the Commercial Code.

The total number of free shares that may be awarded under this authorization may not exceed 5% of the capital on the date of this Meeting.

The award of the shares to the beneficiaries will be final at the end of a vesting period to be determined by the Board of Directors and which may not be less than one year.

The beneficiaries must, as applicable, retain these shares for a period set by the Board of Directors that is at least equal to the time necessary so that the total duration of the vesting periods and, if applicable, the retention period, is not less than two years.

By way of exception, final allocation will take place before the end of the vesting period in the event of disability of the beneficiary classified under the second and third categories set out in Article L. 341-4 of the Social Security Code.

The definitive award of the free shares allotted to corporate officers of the company shall be subject to the achievement of performance conditions to be defined by the Board of Directors.

All powers are granted to the Board of Directors to:
- define the conditions and, as applicable, the award criteria and performance conditions for the shares;
- determine the identity of the beneficiaries and the number of shares allocated to each of them;
- if applicable:
  - record the existence of sufficient reserves and upon each grant of shares, to transfer to a reserve account the sums required to pay up new shares to be granted
  - at the appropriate time, decide on capital increases by means of incorporation of reserves, premiums or profits relating to the issue of new free shares granted,
  - conduct the necessary share acquisitions within the framework of the share buyback program and to allocate them via the allocation plan
  - determine the impacts on the rights of the beneficiaries of transactions that modify the capital or could affect the value of the shares allotted which are executed during the vesting period, and as a result, modify or adjust, if necessary, the number of shares allotted to preserve the rights of the beneficiaries;
  - decide whether to set a retention obligation at the end of the vesting period, and if applicable, define the duration and take all useful measures to ensure compliance by the beneficiaries;
  - and generally, in connection with the legislation in effect, perform all duties that the implementation of this authorization may require.
This authorization will imply that shareholders waive their pre-emptive right to subscribe to newly issued shares through the capitalization of reserves, share premium and profits.

This authorization is granted for a period of thirty-eight months from the date of this Meeting.

It cancels, in the amount, if any, of the unused portion, any prior authorization with the same purpose.

Sixteenth Resolution - Delegation of powers to be granted to the Board of Directors to issue stock warrants (BSA), warrants for new and/or existing shares (BSAANE) and/or warrants for redeemable new and/or existing shares (BSAAR) without preemptive rights, reserved for a category of persons

The Shareholders’ Meeting, after a reading of the Board of Directors’ report and the Statutory Auditors’ special report, and pursuant to Articles L. 225-129-2, L. 225-138 and L. 228-91 of the Commercial Code:

1) Delegates to the Board of Directors its authority to carry out, on one or more occasions, in the proportions and at the times of its choosing, both in France and abroad, the issue of new stock warrants (BSA), equity warrants for new or existing shares (BSAANE) and/or equity warrants for new or existing redeemable shares (BSAAR) eliminating the preemptive right in favor of the categories of persons defined below.

2) Sets the term of validity of this authorization at eighteen months from the date of this Shareholders’ Meeting.

3) Decides that the total par value of the shares to which the warrants issued under this authorization may give rights shall not exceed 0.5% of the capital on the date of this Meeting. To this maximum amount will be added, as necessary, the par value of the ordinary shares to be issued to preserve the rights of the holders of BSAs and/or BSAANEs and/or BSAARs, pursuant to the law, and where applicable, the contractual stipulations providing for other adjustments. This maximum amount is separate from all maximum amounts set by the other resolutions of this Shareholders’ Meeting.

4) Decides that the subscription and/or acquisition price of the shares to which the warrants give rights shall be at least equal to the average closing price of the DBV TECHNOLOGIES share for the 20 trading days preceding the decision to issue the warrants, minus, if applicable, any warrant issue price.

5) Decides to eliminate the preemptive subscription rights of shareholders to the BSA, BSAANE, BSAAR to be issued in favor of the following categories of persons: the corporate officers, members of the scientific committee, the employees of the company, and the persons affiliated under a service or consulting contract with the company and with French or foreign companies affiliated with the company as defined in Article L. 225-180 of the Commercial Code.

6) Stipulates that this authorization means that the shareholders waive their preemptive rights to shares that may be issued by the exercising of warrants to the holders of BSAs, BSAANEs and/or BSAARs.
7) Decides that the Board may not, without prior authorization from the Shareholders’ Meeting, use this delegation during a public tender offer initiated by a third party for the shares of the company until the end of the offer period;

8) Decides that if subscriptions have not absorbed the entire BSA, BSAANE and/or BSAAR issue, the Board of Directors may exercise the following options:
   - limit the issue to the amount of the subscriptions within the limits if any stipulated by regulations,
   - freely allocate all or some of the unsubscribed BSAs, BSAANEs and/or BSAARs to the categories of persons defined above.

9) Decides that the Board of Directors shall be granted all necessary powers, under the terms set by the law and stipulated above, to issue BSAs, BSAANEs and/or BSAARs and in particular to:
   - set the specific list of beneficiaries within the category of persons defined above, the nature and number of warrants to be allocated to each beneficiary, the number of shares to which each warrant shall give entitlement, the issue price of the warrants and the subscription and/or acquisition price of the shares to which the warrants give entitlement under the terms outlined above, the terms and deadlines for the subscription and exercise of the warrants, the associated adjustment mechanisms and more generally, all terms and conditions with respect to the issue;
   - prepare an additional report describing the final terms and conditions of the transaction;
   - conduct the necessary share acquisitions within the framework of the share buyback program and allocate them via the allocation plan;
   - record the completion of the capital increase resulting from the exercising of the BSAs, BSAANEs and/or BSAARs and to amend the Bylaws accordingly;
   - at its sole discretion, charge the costs of the capital increase to the amount of the related premiums and deduct the necessary sums from this amount to bring the legal reserve to one tenth of the new share capital after each increase;
   - delegate to the Chairman and Chief Executive Officer the powers required to execute the capital increase, and to delay the capital increase, within the limits and according to the terms and conditions previously set by the Board of Directors;
   - and more generally, perform all tasks required in similar matters.

The Shareholders’ Meeting notes that this authorization supersedes any and all prior authorizations for the same purpose.

Seventeenth Resolution - Delegation of authority to be granted to the Board of Directors to increase the capital through the issue of shares of common stock and/or securities giving rights to capital, eliminating the preemptive subscription right for the benefit of the members of a company savings plan, pursuant to Articles L. 3332-18 et seq. of the Labor Code

The Shareholders’ Meeting, after a reading of the report of the Board of Directors and the special reports of the Auditors, voting pursuant to Articles L. 225-129-6, L. 225-138-1 and L. 228-92 of the Commercial Code and Article L. 3332-18 et seq. of the Labor Code:

1) Delegates its authority to the Board of Directors, if it deems appropriate and, at its sole discretion, to increase the capital stock on one or more occasions through the issue of shares of common stock or securities giving rights to equity securities of the company to be issued, reserved for members of one or more group or company employee savings
plans established by the company and/or affiliated French or international companies under the conditions of Article L. 225-180 of the Commercial Code and Article L. 3344-1 of the Labor Code.

2) Cancels, in favor of such persons, the preemptive rights to subscribe to shares that may be issued under this authority.

3) Sets the validity of this authorization at twenty-six months from the date of this Shareholders’ Meeting.

4) Limits the maximum par amount of the increase or increases that may be executed under this authority to 2% of the capital stock existing on the date of the Board decision to carry out this increase; this amount is separate from any other ceiling set by other authorizations relating to capital increases. To this total will be added, as necessary, the additional amount of ordinary shares to be issued to preserve the rights of the holders of securities granting access to the Company’s capital, pursuant to law, and any contractual stipulations providing for other adjustments.

5) Decides that the prices of the shares to be issued under point 1/ of this delegation may not be more than 20% lower, or 30% lower, when the lock-in period stipulated by the plan pursuant to Articles L. 3332-25 and L. 3332-26 of the Labor Code is equal to or greater than ten years, than the average of the opening prices listed for the share for 20 trading sessions prior to the Board’s decision on the capital increase and the corresponding stock issue, or greater than this average.

6) Decides, pursuant to Article L.3332-21 of the Labor Code, that the Board of Directors may allocate to the beneficiaries defined in the first paragraph above, free shares already issued or to be issued, or other securities giving access to the Company’s capital issued or to be issued (i) in respect of the contribution that may be paid pursuant to the regulations governing the group or company savings plans and/or (ii) where appropriate, as a discount;

7) Decides that the Board of Directors may not, without prior authority from the Shareholders’ Meeting, use this delegation from the date of filing by a third party of a public tender offer for the company’s shares until the end of the offer period;

8) Notes that this authorization supersedes in the amount of the unused portion, if any, any prior delegation for the same purpose.

The Board of Directors shall have the discretion to implement, or not implement, this authorization, take all measures and conduct all necessary formalities.

Eighteenth Resolution - Amendment to Article 36 of the Bylaws

The Shareholders’ Meeting, after a reading of the report of the Board of Directors decides to:

- harmonize the Bylaws with the provisions of Article L. 823-1 of the Commercial Code as amended by Law 2016-1691 of December 9, 2016;
- accordingly amend as follows Article 36 of the Bylaws; the rest of the article remains unchanged:

“The accounts shall be audited by one or more statutory auditors and, as applicable, alternate auditors, under the conditions defined by Article L. 225-218 of the Commercial Code.”
Nineteenth Resolution - Powers for formalities

The Shareholders’ Meeting grants all powers to the bearer of an original, a copy or an excerpt of these minutes to carry out all mandatory formalities with respect to registration and publication.

Terms and Conditions of Participation

The Shareholders’ Meeting is open to all shareholders, regardless of the number of shares they hold.

The only shareholders who may participate in the Shareholders’ Meeting are those who can demonstrate that they hold a registered account of shares in their name or in the name of the intermediary registered for their account on the second business day preceding the Shareholders’ Meeting, in this case on June 13, 2017, at midnight Paris time:
- either in the registered share accounts kept by the company,
- or in the bearer share accounts kept by the authorized intermediate.

For registered shareholders, simply registering in a share account according to the terms set out above allows them to participate in the Shareholders’ Meeting.

For bearer shareholders, the registration of the shares in the bearer share accounts is established by a shareholding certificate issued by the bookkeeper. To participate in the Shareholders’ Meeting, this shareholding certificate must be sent by the bookkeeper to Société Générale - Shareholders’ Meeting Department - 32, rue du Champ de Tir - CS30812 - 44 308 Nantes Cedex 3 in order to obtain an admission card. Alternatively, the certification may be presented on the day of the Shareholders’ Meeting by shareholders who have not received their admission card.

Shareholders who are unable to personally attend the Shareholders’ Meeting may choose one of the following options:
a) Grant proxy to the person of their choice under the terms set out in Article L. 225-106 of the French Commercial Code;
b) Send a form of proxy to the company without indicating a proxy;
c) Vote by mail.

Registered shareholders who have been registered for at least one month by the date of the notice of meeting will receive by mail the notification brochure along with a single voting form. In any event, by the twenty-first day prior to the Shareholders’ Meeting, the single form for voting by mail or proxy will be posted on the company’s website (www.dbv-technologies.com).

Once the notice of meeting is issued, bearer shareholders may send a written request to Société Générale to send them this form. Any requests received will be granted no later than six days before the Shareholders’ Meeting.

This form must be returned along with the bearer shareholder’s shareholding certificate. The postal vote form must be received by Société Générale’s Shareholders’ Meeting Department by June 11, 2017.

Shareholders who designate a proxy may provide notification of this delegation by e-mailing a signed, scanned copy of the form along with a photocopy of both sides of their ID card and, if applicable, of their shareholding certificate, to investors@dbv-technologies.com, or by faxing these documents to 01.43.26.10.83. A proxy that is granted may also be revoked by the same procedures.
Requests by shareholders to include items or draft resolutions on the agenda must be sent to the registered office by registered letter with acknowledgment of receipt, e-mailed to investors@dbv-technologies.com or faxed to 01.43.26.10.83. These requests must be received no later than the twenty-fifth day preceding the date of the Shareholders’ Meeting. They may not be sent more than twenty days after the date of this notice.

Requests to include items on the agenda must be accompanied by explanations.

Requests to include draft resolutions on the agenda must be accompanied by the text of the draft resolutions, along with, if applicable, a brief explanation of the reasons, and the information stipulated in paragraph 5 of Article R. 225-83 of the French Commercial Code if the draft resolution concerns the nomination of a candidate to the Board of Directors.

A certificate of registration in the shares account must also be attached to these requests to include items or draft resolutions on the agenda in order to prove, on the date of the request, the possession or representation of the required portion of the capital in accordance with the provisions of Article R. 225-71 of the French Commercial Code. A new certificate proving the registration in the shares account in the same accounts on the second business day preceding the Shareholders’ Meeting, at midnight Paris time, must be sent to the company.

The text of the draft resolutions presented by shareholders and the list of items added to the agenda upon their request will promptly be posted on the company’s website (www.dbv-technologies.com).

The preparatory documents for the Shareholders’ Meeting described in Article R. 225-73-1 of the French Commercial Code will be posted on the company's website (www.dbv-technologies.com) no later than the twenty-first day prior to the Shareholders’ Meeting.

Please note that the complete text of the documents intended to be presented to the Shareholders’ Meeting in accordance with, in particular, Articles L. 225-115 and R. 225-83 of the French Commercial Code will be made available at the registered office.

In accordance with Article R. 225-84 of the French Commercial Code, any shareholder may submit, to the Chairman of the Company’s Board of Directors, questions in writing until the fourth business day preceding the date of the Shareholders’ Meeting, in this case until June 9, 2017. Such written questions must be sent either by registered mail including a receipt confirmation form, addressed to the registered office, or electronically to the following address: investors@dbv-technologies.com or by fax to +33 (0)1.43.26.10.83. They must be accompanied by a certificate of account registration.

The Board of Directors